Adaptive Biotechnologies (NASDAQ:ADPT) Insider Susan Bobulsky Sells 3,000 Shares of Stock

Posted by Francis Steltz on Aug 12th, 2026

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) insider Susan Bobulsky sold 3,000 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $25.00, for a total transaction of $75,000.00. Following the transaction, the insider directly owned 396,989 shares of the company’s stock, valued at approximately $9,924,725. This trade represents a 0.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Susan Bobulsky also recently made the following trade(s):

On Thursday, July 30th, Susan Bobulsky sold 1,299 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $24.00, for a total transaction of $31,176.00.
On Wednesday, July 1st, Susan Bobulsky sold 487 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $22.00, for a total transaction of $10,714.00.
On Thursday, June 11th, Susan Bobulsky sold 5,000 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $19.00, for a total value of $95,000.00.
On Thursday, June 4th, Susan Bobulsky sold 11,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $18.00, for a total value of $198,000.00.

Adaptive Biotechnologies Trading Down 0.6%

Shares of NASDAQ ADPT traded down $0.14 during trading on Wednesday, reaching $25.25. The stock had a trading volume of 1,706,441 shares, compared to its average volume of 2,868,770. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79. The company has a market cap of $4.03 billion, a P/E ratio of -61.59 and a beta of 2.08. Adaptive Biotechnologies Corporation has a fifty-two week low of $11.92 and a fifty-two week high of $26.16. The business’s 50-day moving average price is $21.00 and its 200-day moving average price is $17.02.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last announced its earnings results on Wednesday, July 29th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). The firm had revenue of $71.55 million for the quarter, compared to analysts’ expectations of $65.44 million. Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The business’s revenue was up 21.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.17) earnings per share. On average, equities research analysts predict that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Piper Sandler lifted their price objective on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Guggenheim raised their price target on shares of Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. TD Cowen boosted their price target on shares of Adaptive Biotechnologies from $25.00 to $28.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. JPMorgan Chase & Co. reduced their price objective on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Friday, July 17th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Adaptive Biotechnologies currently has a consensus rating of “Moderate Buy” and an average target price of $24.42.

Get Our Latest Stock Report on Adaptive Biotechnologies

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC raised its holdings in shares of Adaptive Biotechnologies by 45.8% in the 1st quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock valued at $2,265,000 after purchasing an additional 97,444 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Adaptive Biotechnologies by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock valued at $511,000 after buying an additional 2,914 shares during the last quarter. Caxton Associates LLP purchased a new position in Adaptive Biotechnologies in the first quarter valued at $93,000. New York State Common Retirement Fund raised its stake in Adaptive Biotechnologies by 39.2% in the second quarter. New York State Common Retirement Fund now owns 47,258 shares of the company’s stock valued at $551,000 after buying an additional 13,300 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its stake in Adaptive Biotechnologies by 728.8% in the second quarter. Arrowstreet Capital Limited Partnership now owns 379,120 shares of the company’s stock valued at $4,417,000 after buying an additional 333,379 shares in the last quarter. Institutional investors and hedge funds own 99.17% of the company’s stock.

About Adaptive Biotechnologies

(Get Free Report)

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.